文献速递复苏、休克与脓毒症创伤与烧伤

使用VS-101(下一代聚乙二醇化血红蛋白氧载体)进行低容量复苏可改善大鼠严重失血性休克后的生存

LOW-VOLUME RESUSCITATION WITH VS -101, A NEXT-GENERATION PEGYLATED HEMOGLOBIN-BASED OXYGEN CARRIER, IMPROVES SURVIVAL AFTER SEVERE HEMORRHAGIC SHOCK IN RATS.
PubMed 文献 · Shock · 2025-02-26
一句话结论在大鼠严重失血性休克模型中,仅VS-101组在8小时观察期末有存活者(67%),平均生存时间426分钟,优于乳酸林格液、血浆和全血。

研究将36只Sprague-Dawley大鼠经压力引导放血45%总血容量造成严重失血性休克,随机给予20%总血容量的乳酸林格液、血浆、全血或VS-101(聚乙二醇化人血红蛋白氧载体)。VS-101组是唯一在8小时观察期末有存活者的组(67%),平均生存时间分别为乳酸林格液49分钟、血浆95分钟、全血197分钟、VS-101 426分钟(P<0.05 vs 所有组)。VS-101产生最高的旋斜方肌间质氧合和平均动脉压恢复,无高血压或小动脉血管收缩证据。作者认为VS-101低容量复苏在模拟院前环境中有效稳定失血性休克,与其高胶体渗透压和携氧成分的组合相关。

要点

  • 大鼠45%总血容量失血性休克模型中,VS-101组8小时存活率67%,为唯一有存活者的组,全血组亦无存活者。
  • 平均生存时间:乳酸林格液49分钟、血浆95分钟、全血197分钟、VS-101 426分钟(P<0.05 vs 所有组)。
  • VS-101产生最高的旋斜方肌间质氧合和平均动脉压恢复,无高血压或小动脉血管收缩证据。
  • VS-101为高氧亲和力、高胶体渗透压的聚乙二醇化人血红蛋白氧载体,设计用于损伤点低容量复苏。

适用人群与场景

  • Sprague-Dawley大鼠,经压力引导放血45%总血容量造成严重失血性休克,模拟院前环境。

处置流程与药物剂量

  • 失血性休克大鼠随机接受20%总血容量的乳酸林格液、血浆、全血或VS-101。

研究设计与关键结果

  • 36只Sprague-Dawley大鼠经压力引导放血45%总血容量后随机分组,每组接受20%总血容量的乳酸林格液、血浆、全血或VS-101。
  • 8小时观察期末仅VS-101组有存活者(67%),即使与全血相比也是如此。
  • 平均生存时间分别为乳酸林格液49分钟、血浆95分钟、全血197分钟、VS-101 426分钟(P<0.05 vs 所有组)。
  • VS-101产生最高的旋斜方肌间质氧合和平均动脉压恢复,无高血压或小动脉血管收缩证据。
  • 作者认为VS-101低容量复苏在模拟院前环境中有效稳定失血性休克,与其高胶体渗透压和携氧成分的组合相关;无小动脉血管收缩和高血压提示VS-101有望通过治疗严重出血的关键安全性和有效性检查点。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠严重失血性休克模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为VS-101低容量复苏在模拟院前环境中有效稳定失血性休克,无小动脉血管收缩和高血压提示其有望通过治疗严重出血的关键安全性和有效性检查点。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Over 30% of trauma-related deaths are from massive hemorrhage with 90% of potentially preventable battlefield deaths occurring prehospital. Immediate resuscitation with whole blood is ideal but often limited to hospital and medical treatment facilities. Shelf-stable hemoglobin-based oxygen carriers (HBOCs) are designed to relieve the hypoperfusion and hypoxia of shock during the critical pre-hospital period. A new PEGylated human HBOC product, VS -101, with high oxygen affinity and hyperoncotic pressure, has been designed for hypovolemic resuscitation protocols at the point of injury. Thirty-six Sprague-Dawley rats underwent a severe, pressure-guided 45% total blood volume (T BV ) hemorrhage. Shocked animals were randomly assigned to receive 20% T BV Lactated Ringers' (LRS), plasma, blood, or VS -101. Cardiovascular parameters, arterial blood gases, 8-h survival, arteriolar diameters, and oxygenation of the spinotrapezius microvasculature were measured. Even compared with whole blood, VS -101 was the only group with survivors (67%) at the end of the 8-h observation period. Mean survival times were 49, 95, 197, and 426 min for LRS, plasma, blood, and VS -101 ( P < 0.05 vs all), respectively. VS -101 produced the highest spinotrapezius interstitial oxygenation and recovery of MAP with no evidence of hypertension or arteriolar vasoconstriction. Hypovolemic resuscitation with VS -101 was effective in stabilizing hemorrhagic shock in a simulated prehospital setting, which was associated with its combination of high oncotic pressure and oxygen carrying constituent. The lack of arteriolar vasoconstriction and hypertension suggests VS -101 is poised to pass critical safety and efficacy checkpoints for treatment of severe hemorrhage.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Nugent WH, Vandegriff KD, Malavalli A, et al. LOW-VOLUME RESUSCITATION WITH VS -101, A NEXT-GENERATION PEGYLATED HEMOGLOBIN-BASED OXYGEN CARRIER, IMPROVES SURVIVAL AFTER SEVERE HEMORRHAGIC SHOCK IN RATS. Shock. 2025. PMID: 40011011. doi:10.1097/SHK.0000000000002570

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。